AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Caillet, Catherine; Piras, Fabienne; Bernard, Marie‐Clotilde; Montfort, Aymeric de; Boudet, Florence; Vogel, Frederick R.; Hoffenbach, A; Moste, Catherine; Kusters, Inca

doi:10.1016/j.vaccine.2010.02.050

Cited by 46 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surface plasmon resonance (SPR) analysis of the antigenicity of immunogen gp140 B.63521 ( Fig. 1) was performed by immobilizing monoclonal antibodies (MAbs) or soluble CD4 (sCD4) to a CM5 sensor chip at about 4,000 response units (RU) using standard amine coupling chemistry as described previously (7,(18)(19)(20). Envelope gp140 B.63521 formulated in PBS (pH 7.4) or in 15% STS adjuvant in PBS (equivalent to the final adjuvant concentration used for immunization studies) for 1 h and diluted to 20 g/ml before being injected for 3 min over the captured MAb or CD4 immobilized surface and binding monitored on a BIAcore 3000 instrument (GE Healthcare Life Sciences, Uppsala, Sweden).…”

Section: Methodsmentioning

confidence: 99%

“…While adjuvant options for human use in the United States have been limited, adjuvants other than alum have been used for veterinary vaccines in the United States (5), and novel adjuvant formulations for use in humans have been licensed outside the United States (6). Studies have shown that adjuvants could permit antigen sparing (e.g., novel influenza vaccines that would require rapid deployment to combat new pandemics [7]) and could increase the potency and breadth of antibody responses (8,9). Adjuvants have also been suggested as a means to overcome the problems of inducing broadly neutralizing antibodies against both HIV-1 and influenza virus (10).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

Moody

Santra

Vandergrift

et al. 2014

J Virol

View full text Add to dashboard Cite

The development of a vaccine that can induce high titers of functional antibodies against HIV-1 remains a high priority. We have developed an adjuvant based on an oil-in-water emulsion that incorporates Toll-like receptor (TLR) ligands to test whether triggering multiple pathogen-associated molecular pattern receptors could enhance immunogenicity. Compared to single TLR agonists or other pairwise combinations, TLR7/8 and TLR9 agonists combined were able to elicit the highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antibodies against the protein immunogen, transmitted/ founder HIV-1 envelope gp140 (B.63521). We further found that the combination of TLR7/8 and TLR9 agonists was associated with the release of CXCL10 (IP-10), suggesting that this adjuvant formulation may have optimally stimulated innate and adaptive immunity to elicit high titers of antibodies. IMPORTANCECombining TLR agonists in an adjuvant formulation resulted in higher antibody levels compared to an adjuvant without TLR agonists. Adjuvants that combine TLR agonists may be useful for enhancing antibody responses to HIV-1 vaccines.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

Moody

Santra

Vandergrift

et al. 2014

J Virol

View full text Add to dashboard Cite

show abstract

“…CoVaccineHTTM, a submicron emulsion of squalene-in-water emulsion containing sucrose fatty acid sulphate esters, has been shown to increase the antibody responses for a whole inactivated influenza A/ H5N1 virus vaccine through TLR4 signaling in mice [144]. AF03, another oil-in-water emulsion adjuvant, was found to induce stronger antibody responses to a pandemic influenza vaccine (at 0.3 µg HA) than non-adju-vanted vaccine in both naive and seasonal flu-primed mice [145].…”

Section: Emulsionsmentioning

confidence: 99%

“…CEL-1000 (18-mer) is an analogue of peptide G (a peptide from human MHCII beta chain, aa [135][136][137][138][139][140][141][142][143][144][145][146][147][148][149], which is known to enhance immune responses of other immunogenic peptides. They can be conjugated to HIV (HGP-30) and malaria peptides as potential vaccines.…”

Section: Specific Peptides/proteinsmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…The primary target for use of these emulsion adjuvants has been pandemic and seasonal inactivated influenza vaccines. All three of these squalene emulsion adjuvants have been found to boost the immune response to both seasonal and pandemic strains of influenza (71)(72)(73)(74)(75)(76). While the frequency of reactions at the injection site for vaccines containing squalene emulsion adjuvants is generally higher than non-adjuvanted vaccines these reactions tend to mild and of short duration (77,78).…”

Section: Emulsionsmentioning

confidence: 99%

A Rational, Systematic Approach for the Development of Vaccine Formulations

Morefield¹

2011

AAPS J

View full text Add to dashboard Cite

Abstract. With the continuous emergence of new infectious diseases and new strains of current diseases, such as the novel H1N1 influenza in 2009, in combination with expanding competition in the vaccine marketplace, the pressure to develop vaccine formulations right the first time is increasing. As vaccines are complex, costly, and have high risk associated with their development, it is necessary to maximize the potential for development of a successful formulation quickly. To accomplish this goal, the historical empirical approach to formulation development needs to be updated with a rational, systematic approach allowing for more rapid development of safe, efficacious, and stable vaccine formulations. The main components to this approach are biophysical characterization of the antigen, evaluation of stabilizers, investigation of antigen interactions with adjuvants, evaluation of product contact materials, and monitoring stability both in real time and under accelerated conditions. An overview of investigations performed for each of these components of formulation development is discussed. The information gained in these studies is valuable in forming the base of knowledge for the design of a robust formulation. With the use of continually advancing technology in combination with maintaining a rational, systematic approach to formulation development, there is a great increase in the probability of successfully developing a safe, effective, and stable vaccine formulation.

show abstract

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Cited by 46 publications

References 14 publications

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

Selection of Adjuvants for Enhanced Vaccine Potency

A Rational, Systematic Approach for the Development of Vaccine Formulations

Contact Info

Product

Resources

About